Tesamorelin 10mg vial

It is used specifically to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, a condition characterized by abnormal fat redistribution due to antiretroviral therapy. Approved by the U.S. FDA in November 2010, tesamorelin is marketed under the brand name Egrifta (available in formulations Egrifta SV and Egrifta WR) and is administered via daily subcutaneous injection.

The drug works by binding to receptors in the pituitary gland, triggering pulsatile release of endogenous GH, which in turn increases insulin-like growth factor-1 (IGF-1) levels. This leads to enhanced lipolysis (fat breakdown), particularly in visceral (deep abdominal) fat stores, while preserving lean muscle mass. Clinical trials have shown tesamorelin reduces visceral adipose tissue by approximately 15% compared to placebo and significantly improves body composition, waist circumference, and metabolic markers like triglycerides and cholesterol.